NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 286 filers reported holding NEKTAR THERAPEUTICS in Q4 2019. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $500,544 | +134.7% | 535,800 | +42.0% | 0.00% | +200.0% |
Q4 2023 | $213,231 | +200.3% | 377,400 | +216.6% | 0.00% | 0.0% |
Q3 2023 | $70,995 | +285.7% | 119,200 | +272.5% | 0.00% | – |
Q2 2023 | $18,405 | +5.2% | 32,000 | +28.5% | 0.00% | – |
Q1 2023 | $17,501 | -93.8% | 24,900 | -80.0% | 0.00% | -100.0% |
Q4 2022 | $281,829 | -58.6% | 124,703 | -41.3% | 0.00% | -66.7% |
Q3 2022 | $680,000 | +129.0% | 212,417 | +171.6% | 0.01% | +100.0% |
Q2 2022 | $297,000 | -46.2% | 78,200 | +91.6% | 0.00% | -40.0% |
Q4 2021 | $552,000 | -85.0% | 40,810 | -80.1% | 0.01% | -87.2% |
Q3 2021 | $3,687,000 | +265.0% | 205,309 | +249.0% | 0.04% | +254.5% |
Q2 2021 | $1,010,000 | +4.8% | 58,829 | +22.1% | 0.01% | -8.3% |
Q1 2021 | $964,000 | -60.7% | 48,199 | -54.5% | 0.01% | -63.6% |
Q2 2020 | $2,456,000 | +170.8% | 106,014 | +112.9% | 0.03% | +22.2% |
Q3 2019 | $907,000 | -59.0% | 49,800 | +139.4% | 0.03% | -83.7% |
Q1 2018 | $2,211,000 | +489.6% | 20,804 | -4.6% | 0.17% | +159.4% |
Q3 2016 | $375,000 | – | 21,803 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rhenman & Partners Asset Management AB | 1,350,000 | $22,950,000 | 1.87% |
MAVERICK CAPITAL LTD | 6,655,625 | $113,146,000 | 1.81% |
Camber Capital Management LP | 2,500,000 | $42,500,000 | 1.49% |
Bellevue Group AG | 3,866,258 | $65,726,000 | 0.75% |
Adero Partners, LLC | 51,500 | $876,000 | 0.75% |
Goodman Financial Corp | 108,342 | $1,842,000 | 0.64% |
CM Management, LLC | 35,000 | $595,000 | 0.55% |
OSTERWEIS CAPITAL MANAGEMENT INC | 424,504 | $7,217,000 | 0.43% |
RICE HALL JAMES & ASSOCIATES, LLC | 568,379 | $9,662,000 | 0.34% |
Burleson & Company, LLC | 107,736 | $1,832,000 | 0.32% |